Arcadia Biosciences (NASDAQ:RKDA) Earns Sell Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Arcadia Biosciences (NASDAQ:RKDA) in a research note issued to investors on Wednesday. The firm set a “sell” rating on the basic materials company’s stock.

Arcadia Biosciences Stock Performance

Shares of Arcadia Biosciences stock opened at $4.50 on Wednesday. The firm has a 50-day simple moving average of $5.40 and a two-hundred day simple moving average of $3.99. The company has a market cap of $6.12 million, a P/E ratio of -1.05 and a beta of 0.88. Arcadia Biosciences has a fifty-two week low of $1.85 and a fifty-two week high of $10.31.

Institutional Trading of Arcadia Biosciences

A hedge fund recently bought a new stake in Arcadia Biosciences stock. Geode Capital Management LLC purchased a new stake in Arcadia Biosciences, Inc. (NASDAQ:RKDA) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 12,297 shares of the basic materials company’s stock, valued at approximately $73,000. Geode Capital Management LLC owned 0.90% of Arcadia Biosciences at the end of the most recent reporting period. Institutional investors own 17.73% of the company’s stock.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.